Medtech company Implantica AG (Nasdaq First North Premier Growth Market:IMP A SDB) on Thursday announced the publication of a real-world study evaluating its RefluxStop device for the treatment of gastroesophageal reflux disease (GERD).
The study, conducted by Priv.-Doz. Dr. Thorsten G. Lehmann, assessed 79 patients at a leading German reflux centre.
Results published in the journal Surgery Open Science demonstrated significant improvements in both proton pump inhibitor (PPI) use and quality of life, even in patients with complex conditions, with median improvements in GERD-HRQL (Gastro-Esophageal Reflux Disease – Health-Related Quality-of-Life) score of 100% and mean improvements of 92.4%.
These findings further support the safety and efficacy of RefluxStop in treating GERD.
Bioretec Ltd secures CE mark approval for RemeOs Trauma Screw portfolio
Biohit launches FAEX Sample System for stool sample collection
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
Innocan Pharma's BI Sky Global completes industry standard safety test
ColdVentures partners with Medco Sports Medicine to combat heat stroke
Median Technologies secures funding for eyonis Lung Cancer Screening software
MicroAire Surgical Instruments acquires NEOSYAD
UCB launches 320 mg/2 mL single-injection administration option for BIMZELX (bimekizumab-bkzx) in US
Concept Medical reports first patient enrolled in MagicTouch SCB trial in peripheral artery disease
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK